FDA Approves Hepatitis C Treatment Ribasphere
December 9, 2005
The Food and Drug Administration has approved the hepatitis C treatment Ribasphere, co-manufactured by Par Pharmaceutical Cos. and Three Rivers Pharmaceuticals LLC, the companies said Monday. FDA approved Ribasphere, which uses the active ingredient ribavirin, in 200 mg, 400 mg and 600 mg tablets for use with interferon alfa-2a to treat hepatitis C.
This article was provided by CDC National Prevention Information Network. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update.